M&T Bank Corp Erasca, Inc. Call Options Transaction History
M&T Bank Corp
- $28.6 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
116Shares Held
74.3MCall Options Held
7.1KPut Options Held
40.1K-
Arch Venture Management, LLC Chicago, IL11.1MShares$32.6 Million33.14% of portfolio
-
Black Rock Inc. New York, NY6.98MShares$20.6 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.17MShares$18.2 Million0.17% of portfolio
-
Artal Group S.A. Luxembourg, N44.72MShares$13.9 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.34MShares$12.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $360M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...